NeoStem Signs Definitive Merger Agreement To Acquire Amorcyte. ICON Acquires Firecrest Clinical. Print E-mail
By Staff and Wire Reports   
Thursday, 14 July 2011 18:16
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 14, 2011.

Neostem Inc. (AMEX:NBS) announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc. (Amorcyte), a development stage cell therapy company focusing on treatments for cardiovascular disease.

Amorcyte's lead product candidate, AMR-001, is ready to initiate a Phase II study for the treatment of acute myocardial infarction (AMI).

ICON plc (NASDAQ:ICLR) announced the acquisition of Firecrest Clinical, a provider of technology solutions that boost investigator site performance and study management.

The terms of the transaction were not disclosed.

Also Thursday:

, a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.  

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.

Cephalon, Inc. (Nasdaq:CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion.

Codexis, Inc. (Nasdaq:CDXS) today announced the company will participate in the 13th Annual Pacific Crest Global Technology Leadership Forum, to be held in Vail, CO on August 7-9, 2011.

NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc. ("Amorcyte"),  a  development stage cell therapy company focusing on novel treatments for cardiovascular disease.

PAREXEL International Corporation (NASDAQ:PRXL) will release financial results for the Fourth Quarter and Fiscal Year 2011 on Tuesday, August 9, 2011 after the close of the stock market.

QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has settled the lawsuit with NURX, its prior Joint Venture partner, with prejudice, and will be focusing its operations to expand its over-the-counter products and laboratory diagnostics to better serve its growing market demands.  

Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic testing, information and services, and Genomic Vision, a biotechnology company dedicated to the development of molecular diagnostics, today announced a multi-year exclusive collaboration involving Genomic Vision's proprietary molecular combing genomic-analysis technology.

Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus